cyrilzakka/clinical-trials huggingface dataset:
Troponin Leaks in Emergency Department Patients Presenting With Supraventricular Tachycardia (SVT)

The goal of this study is twofold. First the investigators would like to determine the trajectory of troponin leaks; if it can be shown that the participants who have only minimal elevations of their repeat troponin universally decrease on the 3rd level then future patients may see significantly improved length of stay. Second, given conflicting results in the literature, the investigators would like to determine if elevated troponin levels correlate to later cardiovascular complications. These complications will be defined as Death, Myocardial Infarction, Cardiovascular intervention (such as coronary artery stenting or bypass). As the investigator is a single hospital system in this county it is uniquely positioned to be able to review this retrospectively.

The investigators therefore propose retrospectively studying participants diagnosed with Supraventricular Tachycardia who had troponin(s) checked in the ED between January 1, 2012 and May 31, 2016 to allow a minimum of a year follow-up for our combined endpoint. The investigators will record the participants troponin value(s) in addition to the age, sex, race, heart rate, creatinine value. The investigators will compare the participants with positive troponins (and hopefully participants with strongly positive troponins) with those who are negative for troponin for presence of the combined end point via chart review.

Eligibility Criteria:
Inclusion Criteria:

* Supraventricular Tachycardia with troponin elevation

Exclusion Criteria:

* Other cardiac arrhythmias or conditions with increased troponin
Acupuncture for Irritable Bowel Syndrome

Little is known about acupuncture's efficacy for Irritable Bowel Syndrome (IBS). This trial uses a manualized acupuncture treatment format that closely follows clinical practice and allows flexibility in designing individualized treatments. In addition, a second parallel qualitative study will follow a subgroup of patients throughout the trial to explore the relationships between patients' interpretations and understandings (what anthropologists call "meaning") of irritable bowel and their response to treatment. Cortisol levels (an important stress hormone) will also be assessed.

This will be a 3-arm trial: Active acupuncture, placebo acupuncture, and wait list.


Eligibility Criteria:
Inclusion criteria:

Diagnosis of Irritable Bowel Syndrome based on Rome II criteria, including at least 12 weeks of abdominal discomfort or pain in the last 12 months with at least 2 of the following features:

* Relief with defecation
* Onset associated with a change in stool frequency
* Onset associated with a change in form/appearance of stool

Exclusion criteria:

* History of severe or intractable IBS, defined as continuous, unremitting and several abdominal pain greater than 12 hours/day
* Previous acupuncture treatment
* Concurrent diagnosis of any bowel disturbance that would interfere with the assessment or safety of the study
* History of laxative abuse
* Previous abdominal surgery (uncomplicated appendectomy, hysterectomy or cholecystectomy at least 6 months prior to entry acceptable)
* History of metabolic or inflammatory disease that may affect bowel motility, eg.g., inflammatory bowel disease, diabetes mellitus, sarcoidosis
* Other significant illness as determined by Investigator
* History of drug or alcohol abuse w/in 2 years;
* Insufficient knowledge of English to complete self-assessments to participate in study
A Study of Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications

The Purpose of this study is to examine whether evidence of channeling exists by analyzing within a cohort of participants with first prescriptions of single-ingredient paracetamol or ibuprofen (or both) whether participants with paracetamol were more likely to have an ibuprofen-related contraindication.


Eligibility Criteria:
Inclusion Criteria:

* Enrolled in up-to-standard practices (practices that have been qualified for research purposes by the Clinical Practice Research Datalink \[CPRD\] administrators) in the CPRD
* Received a first prescription for paracetamol or a first prescription for ibuprofen in 2012
* Were age 18 or older in the date of their qualifying prescription in 2012

Exclusion Criteria:

* Who received a prescription for paracetamol or ibuprofen in the 6 months prior to their qualifying prescription in 2012
* Who received a prescription for any acetaminophen- or ibuprofen-containing combination products in the 6 months prior to the qualifying prescription in 2012
The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study

The purpose of this study is to find out whether short term treatment with a antihypertensive medication prazosin, can influence the levels of a dopamine in the brain. We will examine the levels of dopamine in the the brain using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI). We hypothesize that there will be no significant changes in dopamine levels in healthy individuals taking prazosin.

The purpose of this study is to find out whether short term treatment with a antihypertensive medication prazosin, can influence the levels of dopamine in the brain. We will examine the levels of dopamine in the the brain using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI). The study will involve three PET scans and one MRI. One PET scan will be performed before the participants take prazosin for approximately three weeks, and the last two PET scans will be performed after the prazosin medication phase. We hypothesize that there will be no significant changes in dopamine levels in healthy individuals taking prazosin.

Eligibility Criteria:
Inclusion Criteria:

* Healthy males and females of any ethnic origin between 19 and 45 years old

Exclusion Criteria:

* Use of any illicit drugs in past 3 months prior to randomization and/or have a current or past diagnosis of drug abuse/dependence (including alcohol)
* Current or past DSM-IV diagnosis of any Axis I psychiatric disorder
* Major psychiatric illness and/or substance dependence in first order relatives
* Current active or past suicidal ideation
* Baseline systolic blood pressure outside the normal range
* Current use of medications that could interact with prazosin (e.g. beta blockers, phosphodiesterasetype 5 inhibitors, indomethacin, verapamil, modafinil, clonidine)
* Current use or use during the previous month of medication that may affect the CNS at the time of scanning (e.g. neuroleptics, bupropion)
* Any significant abnormalities in baseline blood results (e.g. CBC, renal and hepatic indicators) or ECG readings that would preclude the use of prazosin
* Pregnancy, trying to become pregnant or breastfeeding
* Presence of metal objects in the body (e.g. some artificial joints, bone pins, surgical clips, skull plate, certain part of dental braces) or implanted electronic devices (e.g. cardiac pacemaker, neurostimulator), that preclude safe MR scanning
* Claustrophobia
* Participation in any nuclear medicine procedures that, including the dose received during participation in this study, will bring the total radiation dose over the currently approved guideline of 20mSv in a 12-month period
* Cardiovascular or cerebrovascular diseases
* History of or current neurological illnesses including seizure disorders, migraine, multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor
* Abnormal body mass (defined as not within 20% of normal BMI
* Learning disability, amnesia or other conditions that impede memory and attention
Single Dose Steroid Before Thyroidectomy for Benign Disease to Improve Postoperative Nausea, Pain, and Vocal Function

The purpose of this study is to evaluate the efficacy of 8 mg of dexamethasone administered prior surgery, to reduce pain, postoperative nausea and vomiting and to improve vocal function after thyroidectomy for benign disease.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Patients undergoing thyroidectomy

Exclusion Criteria:

* Patients who had received antiemetic therapy within 48 hours before surgery
* Patients with depression
* Chronic pain disorder
* Insulin-dependent diabetes mellitus
* History of severe and/or repeated PONV after previous minor surgery, that led to change from standard anesthetic protocol
* Pregnancy
* Age \< 18 years
* Patients who had known malignant disease or had undergone previous thyroid or neck surgery
Pediatric Validation of CONOX Monitor During Surgery

Pediatric Validation of CONOX Monitoring device (qCON and qNOX indices) for anesthesia depth during surgery


Eligibility Criteria:
Inclusion Criteria:

* General Anesthesia using propofol, sevoflurane or desflurane
* ASA I - IV
* Surgical procedure longer than 60 minutes

Exclusion Criteria:

* Neurological disorders
* Inability to correctly place BIS and CONOX probes in forehead
* Pregnancy
* Active prescription for drugs involving chronic pain and / or central nervous system
* Hemodynamic instability
A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

The objective of this study is to evaluate the safety, tolerability, and efficacy of two dose regimens of PF-3463275 compared with placebo added to ongoing atypical antipsychotic therapy for cognitive deficits in subjects with chronic symptoms of schizophrenia.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of schizophrenia
* In stable treatment with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone for at least 2 months
* Stable symptoms of schizophrenia for at least 3 months.

Exclusion Criteria:

* Subjects with a psychiatric disorder other than schizophrenia
* Substance dependence or abuse
* Women who have child bearing potential.
Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment

The study will be non randomized, open label, dose rising study in cancer patients. Cancer treatment is consisting of 2 different drugs: Oshadi D and Oshadi R that will be administered orally.

The study will include two sessions:

* A single dose period to evaluate acute toxicity of each drug
* Consecutive multiple increment dose escalation period of both drugs to determine the long-term safety, and the anticancer activity.


Eligibility Criteria:
Inclusion Criteria:

* Histologically/ cytological proven solid tumor that is metastatic.
* Age \> 21 years old.
* ECOG Performance status \< 2.
* Documented progressive metastatic disease according to RECIST criteria.
* At least one lesion not within prior radiation field that is measurable per RECIST.
* Primary tumor must have been resected.
* Four weeks must elapse from prior therapy.
* Patient has recovered to CTCAE \< Grade 1 from toxicities related to previous treatment (except non-clinically significant AEs).
* Patient must have adequate organ function.
* Sexually active fertile patients and their partners must agree to use medically accepted methods of contraception during therapy and 3 months after the last dose of the study drugs.
* Female patients of childbearing potential must have a negative pregnancy test at screening.
* Patient must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.
* Life expectancy \> 6 months.

Exclusion Criteria:

* Uncontrolled Intercurrent illness or any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results.
* Current or history of hematologic malignancies.
* Patient with positive HIV serology at screening.
* Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.
* Radiation therapy \< 4 weeks prior to screening.
* Patient has received any other type of investigational agent \< 4 weeks prior to screening.
* Metastatic brain or meningeal disease.
* Patient has prothrombin time/International Normalization Ration (PT/INR) or partial thromboplastin time (PTT) test results \> 1.3 UNL.
* Significant swallowing disorders.
* Small bowel surgery.
* Pelvic or abdominal radiation.
* Pre-existing mal absorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption.
* Evidence of concurrent (\< 5 years) second malignancy other than basal cell carcinoma of the skin or cervical carcinoma in situ.
* Mental disorders.
* Inability to give written informed consent.
General Anesthesia/Surgical Exposure on White Matter Development in Children

International large-scale clinical studies have found that prolonged or repeated exposure to general anesthesia drugs in infancy and early childhood can lead to an increased risk of long-term neurodevelopmental abnormalities in children. The study of neurodevelopmental toxicity of general anesthesia drugs is of great social significance. We have established a rhesus monkey model to study the neurodevelopmental toxicity of general anesthetic drugs, the first time to make a preliminary exploration of the mechanism of myelin developmental toxicity of general anesthetic drugs. Several studies using magnetic resonance scanning found a positive correlation between the number of anesthesia exposures and the maturity of distant brain white matter development in juvenile non-human primates. Clinical evidence for myelin developmental toxicity induced by general anesthetic drugs needs to be collected by conducting multicenter and large-sample clinical studies. Earlier studies have either had low sample sizes, which do not allow for better control of confounding factors; or the study population has been limited to specific disease populations, and the results cannot be extrapolated to normal children. In view of this, based on the applicant's earlier study, this project proposes to recruit children who underwent general anesthesia surgery between 0-3 years of age and are now 12-15 years old; children who did not experience surgery between 0-3 years of age were matched by age-sex to serve as a control group. MRI will be used to assess their brain white matter development, to explore the correlation between anesthesia and anesthesia-related factors and brain white matter development and related neurobehavioral development, and to clarify the effects of anesthesia and surgery on children's brain white matter and related neuropsychological development.


Eligibility Criteria:
Inclusion Criteria:

* Currently between 12 and 15 years of age

Exclusion Criteria:

* Surgical complications such as acute infectious diseases, systemic diseases
* Abnormal findings on cerebral white matter and/or neurobehavioral assessment
* History of neonatal ischemic-hypoxic encephalopathy, bilirubin encephalopathy
* Genetic or chromosomal disorders, neurological disorders (including epilepsy, congenital disorders), or a history of craniocerebral trauma, infectious diseases of the central nervous system, febrile convulsions, congenital heart disease, oncological diseases, and blood disorders
* Autism, attention deficit hyperactivity disorder, or those who have received behavioral therapy and intervention.
* Children with organic damage to the nervous system
* Cardiovascular surgery, neurosurgery or intraoperative hemodynamic instability.
Internet-based Perioperative Exercise Program in Patients With Barrett's Carcinoma Scheduled for Esophagectomy

This study will evaluate, if an intensive individually adaptated training program via online supervision during neoadjuvant therapy will improve lung function and reduce pulmonary complications following esophagectomy for Barrett's cancer.

Patients undergoing surgery for esophageal cancer have a high risk for postoperative deterioration of lung function and pulmonal complications. This may be partly due to one-lung ventilation during the thoracic part of the operation. This often encounters for prolonged periods of reconvalescence and reduced quality of life, apart from socioeconomic disadvantages. Physical preconditioning has become a crucial leverage to optimize fitness and lung function in patients scheduled for esophagectomy, in particular during the interval of neoadjuvant therapy.

Eligibility Criteria:
Inclusion Criteria:

* Histologically proven adenocarcinoma of the esophagus or adenocarcinoma of the esophagogastric junction type I according to Siewert's classification, clinical stages IIB-IIIC (T3/T4 and/or N+; M0) according to Union Internationale Contre le Cancer (UICC), 7th Edition
* Resectable stage according to discussion in the local multidisciplinary tumor board (MDT) of the participating centers and patient medically fit for multimodality therapy (ECOG performance status at least 1 or better, no severe impairment of cardiac, renal, hepatic, endocrine, bone marrow and cerebral functions)
* Planned abdominal-thoracic esophagectomy with gastric pull-up and intrathoracic or cervical anastomosis
* Cognitive ability of the patient to understand the perioperative program and to participate actively

Exclusion Criteria:

* Presence of a second malignant tumor (unless curatively treated \> 5 years ago)
* Chemotherapy or radiochemotherapy in patient's history
* Orthopedic, rheumatologic, cardiovascular or neurologic (epilepsy, stroke, Parkinson's disease, muscle wasting diseases such as amyotrophic lateral sclerosis or multiple sclerosis) contraindications for the sports program
* Inability to use the internet or no internet Access
* Inability to communicate in German
* Each active disease, which hinders completion of the study
* Active alcoholism or illegal drug consumption within the last six months before study entry
Sciatic Perineural Versus Stump Catheter for Below Knee Amputation

The goal of this study is to determine if pre-operative placement of the continuous peripheral nerve block by an anesthesiologist using ultrasound technology is more effective than a continuous peripheral nerve block placed during the surgery by a surgeon for patients undergoing a limb amputation

We wish to determine the most effective site for the continuous infusion of local anesthetic for patients undergoing amputation of a limb. The information we obtain from this study will help to decide the most effective manner to provide pain relief for patients in the future. The primary outcome of interest is post-operative pain relief as measured by the amount of pain-relieving medications (opioids) required by patients prior to discharge home. The secondary outcomes of interest will be pain-relieving medications (opioid) requirements during the operation, length of stay in the hospital, time required for mobility, and patient satisfaction- measured by a survey given while in hospital and 3 months later.

Eligibility Criteria:
Inclusion Criteria:

* undergoing a below knee amputation
* 16 years of age or older
* regional anesthetic will be used as part of the surgery

Exclusion Criteria:

* pregnant
* allergic to local anesthetic or ultrasound jelly
* a contraindication to having a peripheral nerve block catheter
Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2

In the stage of randomized controlled study, our purpose is to obtain the Intraoperative anticoagulation program supported by evidence-based medicine.

This study is divided into anticoagulation program in cerebral aneurysm with hybrid operation and anticoagulation program in cerebral arteriovenous malformations with hybrid operation two parts, and each part divide into two stage, on the stage of registration study. This study is a multi-center, single-blind, prospective cohort study. Record the patient's intraoperative activated coagulation time Changes in detail, to observe the effect of activated coagulation time maintenance level on hemorrhage event rate of Intraoperative and postoperative 48 hours, purpose to find out the safety range of activated coagulation time level in cerebral aneurysm and arteriovenous malformations with hybrid operation. On the stage of randomized controlled study. This study is a multicenter, single-blind, prospective, randomized controlled study. Patients is divided into intraoperative standard dose group of Heparin Sodium and low dose group of Heparin Sodium randomly. To observe the effect of different anticoagulation regimens on activated coagulation time safety coverage rate during surgery, and finally develop a scientific and effective intraoperative anticoagulant therapy program.

Eligibility Criteria:
Inclusion Criteria:

1.All patients undergoing hybird surgery.

Exclusion Criteria:

1. Poor general condition , severe primary disease, surgical contraindications
2. Patient or family refused surgery
3. Fusiform aneurysm,Traumatic aneurysm,Infectious aneurysms
4. Combined with other hemorrhagic cerebrovascular disease
5. Combined with malignant brain tumor
6. Perinatal, Pregnancy
7. Patients unwilling to participate in the trial
The Epidemiology of Aortic Diameter in China

Aortic aneurysms are the major disease processes affecting the aorta and becoming a relatively common cause of death because of rupture or dissection. The most common location for aneurysms is the infrarenal abdominal aorta, followed by the ascending thoracic aorta. Unlike coronary heart disease, the incidence of abdominal aortic aneurysm (AAA) in the United States and Europe has been increasing, and this increase may not be due to higher levels of screening for this condition alone. Aortic diameter is central to the diagnosis of aortic aneurysm. Furthermore, it was demonstrated that non-AAA patients with an enlarged diameter of the infrarenal aortic diameter are also at high risk for all-cause mortality. And aortic root dimension was associated with several coronary artery disease (CHD) risk factors and measures of subclinical disease and was predictive of incident congestive heart failure (CHF), stroke, cardiovascular disease (CVD) mortality, and all-cause mortality, but not of incident MI. Up to now, there are limited studies on the epidemiology of aortic diameter, especially in Chinese population.

The purpose of this study was to analyze the size of the entire aorta at different anatomic levels in a large group of Chinese population with clinically evident arterial disease or cardiovascular risk factors to further explored the risk factors and potential alternative pathomechanisms for the development of aortic dilatation. Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels: (1) the annulus, (2) the mid-point of the sinuses of Valsalva, (3) the sinotubular junction, (4) the ascending aorta at the level of its largest diameter, (5) the transverse arch, (6) the descending aorta posterior to the left atrium, and (7) the abdominal aorta just distal to the origin of the renal arteries. The extension of dilation is defined as the number of dilated aortic segments. The relations among aortic dimensions and clinical characteristics will be assessed by multiple regression analysis. The current study was to determine the association of risk factors of CVD and atherosclerosis diseases with aortic dimension in Chinese patients with clinical event atherosclerotic disease or risk factors of atherosclerotic disease.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 40 to 100 were referred to the hospital with a recent diagnosis of clinically evident arterial disease or a cardiovascular risk factor.

Exclusion Criteria:

* Those with connective tissue disease, congenital heart disease, cardiomyopathy, congestive heart failure,rheumatic arthritis, secondary causes of hypertension, or active cancer.